Clearmind Medicine Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
CMND Nasdaq 2830 www.clearmindmedicine.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Clearmind Medicine Inc.

Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial - Sep 11th, 2026 6:00 am
Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results - Sep 8th, 2026 5:42 am
Clearmind Medicine Agrees to Acquire 51% Stake in Charging Robotics for $2.5 Million - Sep 4th, 2026 7:55 am
Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis - Sep 4th, 2026 5:32 am
Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled - Sep 1st, 2026 5:37 am
SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation - Aug 24th, 2026 6:51 am
Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation - Aug 24th, 2026 6:03 am
Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint - Aug 13th, 2026 5:36 am
Clearmind Medicine Announces Positive Permeation Results for Intranasal MEAI Formulation, Supporting Enhanced Nasal Retention Without Compromising Drug Delivery - Aug 11th, 2026 6:05 am
Clearmind Reaches Key Clinical Trial Milestone as DSMB Unanimously Clears Progression in AUD Study - Aug 6th, 2026 6:00 am
Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company - Aug 3rd, 2026 6:02 am
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - Aug 2nd, 2026 4:26 pm
Clearmind Announces Positive Safety Findings for CMND 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in Part A of its FDA-Regulated Clinical Trial - Jul 30th, 2026 6:30 am
Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial - Jul 28th, 2026 5:47 am
Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics Market - Jul 20th, 2026 5:55 am
Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction - Jul 17th, 2026 5:32 am
Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI - Jul 16th, 2026 7:30 am
Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial - Jul 13th, 2026 6:17 am
Clearmind Medicine Responds to the U.S. Administration’s RFI for Addiction Treatment Innovations as Part of the Great American Recovery Initiative - Jul 10th, 2026 6:32 am
Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration Development for MEAI - Jul 7th, 2026 5:42 am